Advertisement

Topics

Shingrix Shingles Vaccine: FDA Wants GSK To Monitor Inflammation Risk

18:51 EDT 11 Sep 2017 | SCRIP

GlaxoSmithKline's vaccine has 97.16% efficacy, surpassing Merck's Zostavax, but US advisory committee will weigh risks from inflammation which could cause...

      

Related Stories

 

Original Article: Shingrix Shingles Vaccine: FDA Wants GSK To Monitor Inflammation Risk

NEXT ARTICLE

More From BioPortfolio on "Shingrix Shingles Vaccine: FDA Wants GSK To Monitor Inflammation Risk"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...